ArticleMedical physics2026
Exploratory personalized radiobiological modeling of bystander and immune effects to inform SFRT-SBRT scheduling.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSpatially fractionated radiation therapy (SFRT) demonstrates clinical efficacy against bulky tumors, but optimal treatment scheduling remains empirical. The technique's heterogeneous dose distribution triggers complex biological effects-including bystander signaling and immune activation-that are not captured by conventional dose-response models. PURPOSE: This study aims to develop a proof-of-concept computational framework to simulate tumor and immune responses during combined Lattice radiotherapy and SBRT) as an initial step toward patient-specific modeling.
methodsA four-compartment ordinary differential equation (ODE) model was established to simulate tumor and lymphocyte dynamics, integrating Gompertz tumor growth kinetics, direct radiation-induced cell killing, and indirect biological effects mediated by intercellular signaling and immune activation. Bystander signaling was described by reaction-diffusion equations modeling spatial propagation from high- to low-dose regions. Immune responses were modeled with coupled lymphocyte-tumor equations, with lymphocyte dose exposure estimated using the HEDOS model. Model parameters were derived from literature and fitted to tumor volume and absolute lymphocyte count (ALC) data from four non-small cell lung cancer (NSCLC) patients treated with SFRT and SBRT.
resultsThe model demonstrated feasibility in reproducing tumor volume (normalized root-mean-square error [NRMSE]: 0.071-0.197) and ALC dynamics (NRMSE: 0.017-0.385). Simulations revealed substantial inter-patient heterogeneity in the estimated contributions of direct radiation and immune-mediated effects, with immune-mediated killing exceeding direct radiation in 2 patients. Combined SFRT-SBRT achieved superior tumor control over either modality alone in our simulations. Notably, the optimal SFRT-SBRT interval appeared patient-specific: extending the interval to 2 months improved outcomes in some patients, while others showed limited benefit, depending on the balance between treatment-induced cell kill and tumor regrowth.
conclusionsWe developed a radiobiological model that simulates tumor and lymphocyte dynamics under combined SFRT-SBRT regimens, providing a preliminary framework for exploring personalized SFRT-SBRT scheduling. These findings warrant further prospective validation in larger patient cohorts before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.